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Abstract
Background/Aims—The onset response to a single tone as measured by 
electroencephalography (EEG) is diminished in power and synchrony in schizophrenia. Because 
neural synchrony, particularly at gamma frequencies (30–80 Hz), is hypothesized to be supported 
by the N-methyl-d-aspartate receptor (NMDAr) system, we tested whether phencyclidine (PCP), 
an NMDAr antagonist, produced similar deficits to tone stimuli in rats.
Methods—Experiment 1 tested the effect of a PCP dose (1.0, 2.5, and 4.5 mg/kg) on response to 
single tones on intracranial EEG recorded over the auditory cortex in rats. Experiment 2 evaluated 
the effect of PCP after acute administration of saline or PCP (5 mg/kg), after continuous 
subchronic administration of saline or PCP (5 mg/kg/day), and after a week of drug cessation. In 
both experiments, a time-frequency analysis quantified mean power (MP) and phase locking factor 
(PLF) between 1 and 80 Hz. Event related potentials were also measured to tones, and EEG 
spectral power in the absence of auditory stimuli.
Results—Acute PCP increased PLF and MP between 10 to 30 Hz, while decreasing MP and PLF 
between ~50–70Hz. Acute PCP produced a dose-dependent broadband increase in EEG power that 
extended into gamma range frequencies. There were no consistent effects of subchronic 
administration on gamma range activity. Acute PCP increased ERP amplitudes for the P16 and 
N70 components.
Conclusions—Findings suggest that acute PCP induced NMDAr hypofunction has differential 
effects on neural power and synchrony which vary with dose, time-course of administration and 
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EEG frequency. EEG synchrony and power appear to be sensitive translational biomarkers for 
disrupted NMDAr function, which may contribute to the pathophysiology of schizophrenia and 
other neuropsychiatric disorders.
Keywords
NMDA receptor antagonism; phencyclidine; auditory ERP; neural synchrony; schizophrenia; rat 
model
Introduction
Schizophrenia is characterized by both auditory hallucinations and distortions in auditory 
perception [1]. Consistent with these subjective and behavioral disturbances of auditory 
processing, one of the most common neurobiological findings in schizophrenia is reduction 
in the amplitude of N100 components of the event-related potential (ERP) elicited by tones 
or clicks [2]. While the majority of studies of ERPs in schizophrenia have measured these 
responses in the time domain, there has been increasing interest in utilizing time-frequency 
analytic techniques to differentiate the early auditory response between frequency bands. 
The gamma frequency band (30–80 Hz) has been of specific interest because it has been 
associated with the neural processing of sensory stimuli as well as perceptual and cognitive 
integration [3,4].
In individuals with schizophrenia, a decrease in gamma range power [3,5–8] or phase-
locking factor [9] in the EEG after the onset of single tones has been observed by most [9] 
but not all studies [10,11]. Hall et al. (2011) used a twin design and found that auditory 
gamma-band power and phase locking to standard tones in an auditory oddball paradigm 
were heritable responses associated with schizophrenia: both patients with schizophrenia 
and their non-psychotic co-twins showed reduced gamma power [3]. The pathophysiological 
mechanisms responsible for deficits in auditory gamma-band activity in schizophrenia have 
focused on the role of the parvalbumin-positive gamma-amino butyric acid (GABA) receptor 
and to N-methyl-d-aspartate receptor (NMDAr) [4,12–14]. Both in vitro and in vivo 
evidence suggest that excitatory principal neurons, parvalbumin inhibitory interneurons, 
subtype A of the gamma-amino butyric acid receptor family (GABAA), and NMDAr 
modulate neural synchrony in the gamma frequency range [15–18]. NMDAr antagonists are 
believed to block NMDA receptors on GABAergic neurons largely in the corticolimbic, 
thalamocortical and intracortical neural circuits, causing disinhibition of pyramidal neurons 
and an increase in dopamine in the prefrontal cortex (PFC) [19,20]. Since NMDAr 
abnormalities have been implicated in the pathophysiology of schizophrenia [21], it has been 
argued that NMDAr hypofunction may contribute to the observed deficit in neural synchrony 
in the gamma frequency range (40–50 Hz) in responses evoked by auditory stimuli [4,9,13]. 
The effects of NMDAr antagonists on gamma oscillations, however, vary with experimental 
manipulations, paradigms, and recording procedures. Ex vivo recordings from mice [22] and 
rats [23] indicate that chronic ketamine exposure suppresses spontaneous gamma 
oscillations. However, acute in vivo administration of NMDAr antagonists generally 
increases spontaneous gamma activity in rodent electroencephalography (EEG) and local 
field potentials (LFP) [17,24].
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Few studies have examined the effect of NMDAr antagonism or hypofunction on gamma 
activity evoked by single tones or clicks, and results have varied across paradigms. Gandal 
and colleagues (2012) tested mice that were genetically engineered to have an 85% 
downregulation of the NMDAr system [25]. Compared to wild-type mice, the NMDAr 
knock-down mice demonstrated selective reduction of gamma range power to click stimuli, 
suggesting NMDAr hypofunction as a possible mechanism for impaired gamma neural 
oscillatory behavior. In contrast, Ehrlichman et al. (2009) found that acute pharmacologic 
administration of ketamine in mice did not have a significant effect on evoked gamma power 
to click stimuli [26]. In humans, Hong et al. (2010) found that subanesthetic ketamine 
increased gamma-band oscillations elicited by click stimuli in a sensory gating paradigm 
[27]. One factor that may account for differences among studies is the dose of the NMDAr 
antagonist or degree of genetically manipulated receptor hypofunction. With auditory steady 
state responses (ASSRs), for example, high levels of NMDAr blockade may be required to 
reduce gamma synchrony [14,28]. Secondly, subchronic or chronic administration using 
either multiple single doses or continuous delivery of NMDAr antagonists may have quite 
different physiological effects [29]. Studies using MK-801 [30] and PCP found that acute, 
but not subchronic administration of a NMDAr antagonist, reduced ASSR gamma phase 
synchrony in rats [30][28].
The aim of the present study was designed to address these issues, examining intracranial 
EEG responses measured in both the time and frequency domains. In Experiment 1, the 
effects of three different subcutaneous doses of PCP (1, 2.5, and 4 mg/kg) were evaluated. In 
Experiment 2, the effects of acute and subchronic administration of PCP were evaluated. In 
both experiments, three electrophysiological measures were characterized including time 
domain evoked responses to tones, time-frequency measures of evoked power and phase 
synchronization to tones, and the frequency power spectrum in the absence of tone stimuli. It 
was hypothesized that 1) acute PCP would increase the amplitude of evoked responses in the 
time domain and decrease responses after subchronic administration, 2) both acute and 
chronic administration of PCP would suppress gamma activity in the frequency domain and 
3) acute PCP would produce a broadband increase in EEG spectral power in the absence of 
tone stimuli, consistent with prior studies. This study makes unique contributions in that it 
evaluates evoked responses to tones 1) at different levels of NMDAr pharmacological 
antagonism, 2) in both the time and frequency domains, 3) for both acute and subchronic 
PCP administration and 4) in comparison with non-evoked (resting) EEG activity.
Materials and Methods
Ethics
The research facilities were accredited by the Association for Assessment and Accreditation 
of Laboratory Animal Care (AAALAC). All procedures were approved by the Institutional 
Animal Care and Use Committee (IACUC) at Indiana University (Reference number: 
0000003253) in compliance with the guidelines of the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals. The minimal numbers of animals required 
were used, and efforts were made to minimize all pain and suffering. An isoflurane/air 
mixture was used for general anesthesia during surgical procedures, and methods of 
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euthanasia were based on recommendations of the Panel of Euthanasia of the American 
Veterinary Medical Association.
Animals
Adult male (300 g) Sprague-Dawley rats were obtained from Harlan Laboratories 
(Indianapolis, IN) and were acclimated to the facilities for seven days before being 
individually housed. Food and water were available ad libitum.
Electrode implantation
The procedure for electrode implantation was completed as described in Leishman et al. 
(2015) [28]. In short, at 12 weeks old (369 ± 6 g), rats were anesthetized and stainless steel 
screw electrodes were epidurally implanted over the temporal cortex, cerebellum (ground), 
and frontal sinus (reference). Rats were given two weeks of recovery before beginning EEG 
recordings.
Stimulation, EEG recording and PCP administration
Rats were awake and allowed to move freely during the recordings, which occurred at the 
same time of day for each animal. Rats were allowed 30 minutes to acclimate to the 
recording environment. EEG recordings began 20 minutes after injection to allow for drug 
absorption in treated animals with a baseline EEG recording of 78 s without auditory stimuli 
followed by a tone paradigm. The tone paradigm included the presentation of 100 single 
tones via a speaker above the animal enclosure. Tones (1000 Hz, 85 dB, and with a 50 ms 
rise fall time) were 1000 ms in duration and were presented at a 1000 ms inter-trial interval. 
Continuous EEG (bandpass 1–200 Hz) was recorded with a digitization rate of 1000 Hz 
(Contact Precision Instruments, Cambridge, MA) and saved for off-line processing. EEG 
was analyzed using Brain Vision Analyzer (Brain Products GmbH, Munich, Germany) and 
MATLAB (The MathWorks, Natick, MA).
Experiment 1: Dose-response effects of PCP
On day 1, all rats (N= 10) were subcutaneously injected with saline (pH ~7.5) and baseline 
recordings were collected at rest. One week following baseline measures, rats received a 
dosing regimen of 1.0, 2.5, and 4.0 mg/kg PCP (pH~7.8) in randomized order. PCP doses 
were given one week apart to avoid carry-over effects. One week after the last dose of PCP, 
rats received an injection of saline and washout responses were recorded. All resting state 
(freely moving) EEG recordings were collected 20 minutes after drug injection.
Experiment 2: Acute versus subchronic effects of PCP
Rats (N=21), different from those included in Experiment 1, were randomly assigned to 
either a PCP (n=10) or saline control group (n=11). On day 1, all rats were subcutaneously 
injected with saline and baseline EEG recordings were obtained. Ninety minutes later, rats 
were injected with saline or PCP (5 mg/kg), depending on group randomization, and acute 
responses were obtained. This dose of PCP increased locomotor activity and stereotyped 
behaviors, consistent with previously reported observations after acute subanesthetic PCP 
administration [31–33]. On day 4, each rat was implanted between the scapulae with an 
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osmotic mini pump (model 2ML2, Duret Corp., Cupertino, CA) that subcutaneously 
delivered either saline or PCP (5 mg/kg/day) for 14 days. Continuous subchronic 
administration of PCP produces a lower peak serum level than a single acute injection [34–
36], with two weeks of continuous PCP administration at 5 mg/kg/day producing serum 
levels of about 16 ng/ml [35]. Similar subchronic dosages of continuous or repeated PCP 
administration have produced impairments in extradimensional shift learning [37], novel 
object recognition [38], and potentiation of amphetamine-induced locomotion [35]. On day 
18, EEG recordings were obtained to evaluate the effect of subchronic PCP exposure. After 
25 days (7 days after cessation of drug delivery), EEG recordings were again collected. 
Three rats included in the analysis did not have a saline injection prior to their baseline 
recordings.
EEG data processing and outcome measures
For both Experiment 1 and 2, three types of analyses were used: 1) event-related potentials 
(ERP) to tone onset in the time domain, 2) time frequency analysis of the tone response, and 
3) power spectra analysis of baseline EEG without auditory stimulation. For the ERP 
responses in the time domain, the onset of the tone elicited a large positive deflection with a 
mean latency of 16 ms (P16), and a negative deflection with a mean latency of 70 ms (N70) 
in the baseline saline condition (Figure 1A). For each rat and condition, EEG was segmented 
into 600 ms epochs with a 100 ms prestimulus baseline period and a 500 ms post-trial 
period. Automatic artifact rejection removed trials with any data point outside the range of 
± 450 µV across conditions. Epochs were averaged and baseline and corrected by 
subtracting the average baseline value from all of the sample points in the epoch. P16 was 
measured as the most positive peak in the 14 to 24 ms range, and N70 as the most negative 
peak in the 55 to 100 ms range.
For the time frequency analysis of tone responses, raw data were segmented into 1500 ms 
epochs with a 250 ms baseline and 1250 ms post-trial period. Automatic artifact rejection 
removed trials containing data points outside the range of ± 450 µV. FFT spectrograms were 
calculated with a moving window of 128 ms, a time step of 10 ms, and a pad ratio of 2 for 
each trial and channel. The frequency data was separated into eight 10 Hz step frequency 
bins as follows: Bin 1= 1 to 9.8 Hz, Bin 2 = 9.9 to 19.6 Hz, Bin 3 = 19.7 to 29.4 Hz, Bin 4 = 
29.5 to 39.2 Hz, Bin 5= 39.3 to 49.0 Hz, Bin 6= 49.1 to 58.8 Hz, Bin 7 = 58.9 to 68.6 Hz, 
and Bin 8= 68.7 to 78.4. Phase locking factor (PLF) and mean power (MP) were calculated 
for the onset response, the period between 0 ms (stimulus onset) to 50 ms after stimulus 
onset, for each condition (Figure 2). PLF, also known as intertrial phase coherence, is an 
index of phase synchronization across trials at particular temporal intervals and frequencies. 
PLF is the average of normalized phase across trials for every time point and frequency, and 
it is measured between 0 (no synchrony), to 1 (perfect synchrony) [39]. MP measures the 
power in a specific frequency band relative to baseline and includes both synchronous and 
unsynchronized activity [40].
For baseline EEG without stimulation (“resting”), raw data recorded from the temporal 
electrode was segmented into 5 s intervals, and automatic artifact rejection was used to 
remove segments outside of ± 450 µV in amplitude. Next, a Fast Fourier Transform (FFT) 
Schnakenberg Martin et al. Page 5
Neuropsychobiology. Author manuscript; available in PMC 2018 October 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
was calculated with a Hanning window of 20%, and segments were averaged. Mean values 
were exported for eight 10 Hz step frequency bins consistent with the time-frequency 
analysis.
Statistical analysis
For Experiment 1, an analysis of variance (ANOVA) was conducted with the repeated 
measure factor of Dose (5: baseline, 1.0 mg/kg, 2.5mg/kg, 4.0mg/kg, washout) to assess 
each outcome measure. When the Mauchley test for sphericity was significant (p < .05), the 
Geisser-Greenhouse correction was used for significance testing. When an ANOVA 
indicated significant differences between doses, paired sample t-tests were conducted 
between the baseline and the four other conditions (1.0 mg/kg, 2.5mg/kg, 4.0mg/kg, and 
washout). Bonferroni corrections were applied for multiple comparisons, and a p value ≤ .
0125 (.05/4) was considered statistically significant. For outcome measures in Experiment 2, 
a repeated measures ANOVA was conducted with the repeated measure factor of Time (4: 
baseline, acute, subchronic, washout) for each condition (saline or PCP). When an ANOVA 
indicated significant effects of time, a paired samples t-test was conducted between the 
baseline and three other conditions (acute, subchronic and washout). Bonferroni corrections 
were applied for multiple comparisons, and a p value ≤ .017 (.05/3) was considered 
significant.
Results
Experiment 1: Dose-response effects of PCP
ERP Time Domain Analyses—There was no effect of Dose for P16 latency, P16 
amplitude or N70 latency. There was a main effect of Dose for N70 amplitude (p = .029). 
Paired t-tests with showed a trend for an increased N70 amplitude to the 4.0 mg/kg dose 
(t(9)=3.03, p = 0.014) and an increase at the washout recording (t(9) = 3.72, p = .005). 
Figure 1A–B depicts the ERP waveforms and amplitude for the N70 ERP component.
Time-Frequency Analysis: Phase Locking Factor—PCP increased PLF at lower 
frequencies (~20 to 30 Hz) and decreased PLF at higher frequencies (~50–70 Hz) at select 
doses of PCP (Figure 2A–B). There was a significant effect of dose in Bin 3 between 19.7 to 
29.4 Hz (F(4,6) = 5.10, p = .002), Bin 6 between 49.1 to 58.8 Hz (F(4,6) = 4.07, p = .008), 
Bin 7 between 58.9 to 68.6 Hz (F(4,6) =7.48, p <.001), and Bin 8 between 68.7 to 78.4 Hz 
(F(4,6) = 9.13, p < .001). Post-hoc analyses determined that there were decreases in PLF 
between baseline and 1.0 mg/kg in Bin 7 (58.9 to 68.6 Hz) (t(9)=3.23, p = .010) as well as 
between baseline and 2.5 mg/kg in Bins 6 (49.1 to 58.8 Hz) and 7 (58.9 to 68.6 Hz) 
(t(9)=3.12, p = .012 and t(9)=3.44, p = .007, respectively). Additionally, there was an 
increase in PLF between baseline and 4 mg/kg in Bin 3 (19.7 to 29.4 Hz) (t(9) = −3.73, p = .
005). There were no significant differences between baseline and washout conditions.
Time-Frequency Analysis: Mean Power—PCP administration decreased MP at high 
frequencies (~50 to 70 Hz) across all doses (Figure 2C–D). There was an effect of dose in 
Bin 6 between 49.1 to 58.8 Hz (F(4,6)=4.44, p=.005), Bin 7 between 58.9 to 68.6 Hz 
(F(4,6)=3.36, p = .020), and in Bin 8 between 68.7 to 78.4 Hz (F(4,6) = 3.73, p = .012). 
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Post-hoc analyses with paired sample t-tests determined that there were decreases in power 
between baseline and 1.0 mg/kg in Bin 7 (58.9 to 68.6 Hz) (t (9)=3.14, p = .012), between 
baseline and 2.5 mg/kg conditions in Bins 6 and 7 (49.1 to 68.6 Hz) ((t(9) =4.72, p = .001, 
and t(9) = 3.12, p = .009, respectively), as well as between baseline and 4.0 mg/kg in Bins 6 
and 7 (49.1 to 68.6 Hz) ((t(9) = 5.66, p < .0.001, and t(9) = 4.23, p = .002, respectively). 
There were no significant differences between baseline and washout conditions.
Resting EEG Power Spectrum—PCP administration increased spectral power across 
frequencies (Figure 3A). There was an effect of dose in Bin 2 between 9.9 to 19.6 Hz 
(F(4,6)= 5.10, p= .039), Bin 3 between 19.7 to 29.4 Hz (F(4,6) = 4.33, p = .005), Bin 4 
between 29.5 to 39.2 (F(4,6) = 8.56, p = .012), Bin 5 between 39.3 to 49.0 (F(4,6) = 15.64, p 
= .003), Bin 6 between 49.1 to 58.8 Hz (F(4,6)= 18.63, p=.002), Bin 7 between 58.9 to 68.6 
Hz (F(4,6)= 28.20, p < .001), and in Bin 8 between 68.7 to 78.4 Hz (F(4,6) = 17.80, p = .
002). Post-hoc analyses with paired sample t-tests determined that there were increases in 
power between baseline and 1.0 mg/kg in Bins 4 through 8 (29.5 to 78.4 Hz) ((t(9) > −3.53, 
p < .007 for all tests). Significant increases in spectral power were observed between 
baseline and 2.5 mg/kg in Bins 4 through 8 (29.5 to78.4 Hz) ((t(9) > −5.94, p < .001 for all 
tests). Increases in spectral power were also observed between baseline and 4 mg/kg in Bins 
2 through 8 (9.9 to78.4 Hz) ((t(9) > 3.72, p < .006 for all tests). There were no significant 
differences in power between baseline and washout conditions.
Experiment 2: Acute versus subchronic effects of PCP
ERP Time Domain Analyses—P16 amplitude increased after acute PCP administration 
(t(9) = 3.815, p = .004) and returned to baseline values after 14 days of subchronic PCP 
treatment (F(1.67) = 5.19, p = .006). Similarly, acute administration of PCP resulted in a two 
fold increase in N70 amplitude (t(9) = 3.93, p < .001), which then returned to baseline range 
values (F(1.31, 27) = 14.01, p = .002). In contrast, changes over time occurred in the saline 
group which likely reflect developmental changes over the course of the study. In the saline 
condition, N70 latency decreased across recording sessions (F(3,30) = 10.54, p < .001) at the 
trend level at 14 days (t(10) = 2.31, p = .04) and significantly at 21 days (t = 5.94, p < .001). 
Similarly, N70 amplitude increased over sessions (F(1.63, 30) = 27.25, p < .001) at 14 days 
(t(10) = 5.69, p < .001) and 21 days (t(10) = 6.28, p < .001). Overall, these results suggest 
that the PCP administration resulted in a transient increase in N40 amplitude, but then 
interfered with developmental changes in the N40 latency and amplitude over the course of 
the study period. See Figure 1C–E for the ERP waveform (1C) and changes in amplitude of 
the N70 (1D) and P16 (1E) ERP components.
Time-Frequency Analysis: Phase Locking Factor—Compared to saline, acute PCP 
administration increased PLF at lower frequencies (~10 to 30 Hz) and decreased PLF at 
higher frequencies (~40 to 80 Hz) (Figure 2E–F). There was a significant effect of time in 
the PCP group for Bin 2 between 9.9 to 19.6 Hz (F(3,7) = 5.89, p = .003) and Bin 3 between 
19.7 to 29.4 Hz (F(3,7) =7.05, p = .001) (10 to 30 Hz). Post-hoc analyses demonstrated a 
statistically significant increase in PLF between baseline and acute conditions in Bin 2 (t(9)=
−4.39, p=.002) and Bin 3 (t(9)= −4.39, p = .002) (9.9 to 29.4 Hz). There was also a 
significant effect of time in the PCP group for Bin 5 to 8 (39.3 to 78.4 Hz (F(3,7) > 4.58, p < 
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0.020). Post-hoc analyses demonstrated statistically significant decreases in PLF between 
baseline and acute conditions within Bins 5, 6 and 8 (t (9)= 4.06, p =.003; t(9)=4.55, p = .
001; t(9)= 4.47, p =.002, respectively). Additionally, PLF increased between baseline and 
washout in Bin 2 only (t(9)= −3.18, p = .011). There were no significant effects of time for 
the saline group.
Time-Frequency Analysis: Mean Power—Compared to the saline, acute PCP 
administration increased MP at lower frequencies (~10 to 30 Hz) (Figure 2G–H). In the PCP 
group, there was a significant effect of time in Bin 2 between 9.9 to 19.6 Hz (F(3, 7) = 7.30, 
p = .001) and Bin 3 between 19.7 to 29.4 Hz (F(3,7) = 8.18, p <.001). Post-hoc analyses 
revealed that there was an increase in MP in both Bins 2 and 3 (9.9 to 29.4 Hz) between 
baseline and acute conditions (t(9)= −4.20, p = .002; t(9) = −4.05, p = .003, respectively). 
There was also a significant effect of time in Bin 8 between 68.7 to 78.4 Hz (F(3,7) = 4.62, p 
= .01), however no post-hoc comparisons were significant. There was, however, a trend for 
decreased MP in the acute condition (t(9)=2.789, p =.021). In the saline group, EEGs 
showed a change from baseline (p<.05) for Bin 3 only (F(3,8) =3.41, p = .030) (19.7 to 29.4 
Hz), with post-hoc comparisons showing an increase in MP between baseline and the 
subchronic condition (t(10)= −3.85, p=.003). There were no statistically significant 
differences between baseline and washout conditions for either group.
Resting EEG Power Spectrum—Acute PCP administration increased spectral power 
(Figure 3C), compared to saline (Figure 3B), for most frequencies. In the PCP group, there 
was a nearly significant effect of time in Bin 2 (9.9 to 19.6 Hz) ((F(3,7) = 4.19, p = .054) and 
significant effects for Bins 3 through 8 (19.7 to 78.4 Hz, F(3,7) > 5.59, p < .029 for all 
ANOVAs). Post-hoc analyses demonstrated significant increases in spectral power between 
baseline and acute conditions between Bins 2 through 8 (9.9 to78.4 Hz) (t(9) > 3.19, p <.012 
for all tests). Significant increases in power were also observed between baseline and 
subchronic administration for Bins 6 and 7 (49.1 to 68.6 Hz) (t(9) = 3.19, p = .011) and (t(9) 
= 3.02, p = .014), respectively). There were no significant differences in power observed in 
the PCP administration group between baseline and washout. There was a significant effect 
of time for the saline group observed in Bins 5 through 8 (39.3 to 78.4 Hz) ((F(3,7) = 4.54, p 
= 0.39), (F(3,7) = 7.97, p = .009), (F(3,7) = 6.23, p = .017), and (F(3,7) = 6.55, p = .015), 
respectively). Post-hoc analyses demonstrated, however, only a significant difference in Bin 
5 (39.3 to 49.0) between baseline and washout conditions (t(9) = −3.70, p = .004).
Discussion
Acute in vivo administration of PCP produced pervasive dose-related alterations in the 
neural response to a single tone in rats. As hypothesized, NMDAr antagonism suppressed 
gamma-band neural activity (~50–70 Hz) in response to auditory stimuli, while 
simultaneously increasing neural synchrony and power at lower frequencies (i.e., 10–30 Hz). 
These results support a possible role for NMDAr hypofunction in gamma frequency band 
deficits observed in schizophrenia. The magnitude of these effects were dose-dependent, 
with higher doses of acute PCP producing greater gamma suppression. In contrast, acute 
PCP produced a broad band, dose-dependent increase in resting spectral power including 
gamma range activity. Continuous, low level administration of PCP (5 mg/kg/day) had little 
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effect on neural power or synchrony in response to a single tone or to resting EEG spectral 
power.
The suppression of high frequency gamma activity by PCP in the present study is similar to 
several other studies of auditory ERPs in rodents with NMDAr function impaired through 
genetic manipulations [25] and other NMDAr antagonists, such as MK-801 [30], ketamine 
[14], and PCP [28]. In contrast, relatively low dose ketamine administration in humans [27] 
and mice [26] failed to suppress auditory evoked gamma activity. These divergent results 
may be related to the level of NMDAr suppression by each manipulation. For instance, high 
levels of NMDAr suppression (> 80% receptor occupancy) by PCP, ketamine, or genetic 
inactivation of NMDAr channels may reduce auditory gamma synchrony, whereas low levels 
of NMDAr suppression may increase gamma synchrony.
These findings suggest that PCP induced NMDAr hypofunction increases both power and 
neural synchrony at low frequency oscillations. Beta neural synchrony (15–30 Hz) has been 
suggested to be responsible for multi-modal binding across long-range neural networks [41]. 
The elevated low frequency neural synchrony and power in response to PCP administration 
is similar to our previous findings with ASSRs [28] and the broadband increase in 
spontaneous EEG activity commonly elicited by NMDAr antagonists. The cellular 
mechanisms for a PCP-induced increase in alpha and low gamma range activity generated 
by auditory stimulation are not well understood. Computational modeling by Spencer (2009) 
suggested that reducing NMDAr input to fast spiking interneurons increases network 
excitability, including gamma power [42].
Experiment 2 suggested that acute administration of 5 mg/kg has a larger physiological 
impact than the same dose over an extended period of time. Similarly, acute NMDAr 
antagonist administration, but not subchronic administration, reduced gamma range activity 
in the auditory steady state response in rats [28,30]. Steady-state serum levels associated 
with continuous administration are much lower than the maximum concentration in response 
to the same amount of drug produced by injection. In addition, changes in neurotransmission 
occur with continued exposure, as acute PCP administration increases glutamate in the 
prefrontal cortex, while chronic administration decreases the production of dopamine and 
glutamate [29,43,44]. It has also been shown that acute PCP administration impairs temporal 
cortex function, although it may be unaffected by chronic exposure [29].
The early auditory ERP components to tone onset increased in amplitude to acute PCP, 
different from the usual reduction in early auditory ERP amplitude in schizophrenia. 
However, in Experiment 2 there was an increase in N70 amplitude in the saline arm over 
time which failed to occur in the PCP arm, which suggests that NMDAr hypofunction could 
result in smaller auditory ERPs over development. The relationship between auditory evoked 
potentials elicited by a single tone and the course of schizophrenia or in high-risk groups has 
not been well characterized, although gamma-band neural synchrony deficits in auditory 
evoked potentials have been found in the relatives of patients with schizophrenia, suggesting 
an effect of genetic risk in the absence of psychotic symptoms [27,45].
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There are several important limitations regarding the mechanistic implications of the present 
data. First, in vivo administration affected NMDAr in the entire brain, and therefore direct 
effects on local auditory circuits cannot be differentiated from modulation of auditory 
circuits by projections from other brain regions. Second, the continuous dosing using an 
osmotic mini-pump may not have maintained levels of PCP in the CNS sufficient to impact 
EEG measures. Finally, though the auditory cortex recording site in the present study was 
proximal to the primary generator of the neural response to the single tone, it is unclear 
which intracranial recording sites in rats generate activity most similar to that recorded from 
scalp electrodes in humans.
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Figure 1. ERP Time Domain Analyses
Analyses for Experiment 1 and 2 are displayed in the left and right columns, respectively. 
The figure depicts the ERP waveforms for the P16 and N70 ERP components across all 
doses in Experiment 1 (baseline, 1.0 mg/kg, 2.5 mg/kg, 4 mg/kg and washout) (Fig.1A) and 
time in Experiment 2 for the PCP arm (baseline, acute PCP, subchronic PCP and washout 
conditions) (Fig. 1C). Figure 1 also displays the change in N70 (Figs. 1B and 1D) and P16 
(Fig. 1E) amplitudes. All comparisons are in relation to the baseline condition, and asterisks 
and p-values refer to Bonferroni adjusted significance levels.
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Figure 2. Time-Frequency Analyses
Analyses for Experiment 1 and 2 are displayed in the left and right columns, respectively. 
The figure shows phase locking factor (PLF) (Figs.2A and 2E) and mean power (MP)(Figs. 
2C and 2G) across all doses in Experiment 1 (baseline, 1.0 mg/kg, 2.5 mg/kg, 4 mg/kg and 
washout) and time in Experiment 2 for the PCP arm (baseline, acute PCP, subchronic PCP 
and washout) with exemplary spectrograms of PCP effects (Figs. 2B and 2F (PLF) and 2D 
and 2H (MP)). MP is shown in microvolts2 (µV2) and PLF is depicted from 0 to .9, 
indicating minimum to maximum synchrony. Statistically significant differences (p<.05) 
from baseline are indicated with colored asterisks (*); the color of the asterisks corresponds 
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with the condition in which a significant difference from baseline was observed. Statistically 
significant differences (p<.05) from baseline are indicated with an asterisk (*), and represent 
Bonferroni adjusted significance levels.
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Figure 3. Resting State Power Spectrum
Analyses for Experiment 1 and 2 are displayed in Figures 3A–C. Figure 3A depicts spectral 
power across all doses in Experiment 1 (baseline, 1.0 mg/kg, 2.5 mg/kg, 4 mg/kg and 
washout). Figures 3B and 3C depict the changes in spectral power in both the saline (3B) 
and PCP (3C) arms of Experiment 2 (conditions: baseline, acute PCP or saline, subchronic 
PCP or saline, and washout). Power spectra was measured microvolts2 and plotted in 
logarithmic mean values. Statistically significant differences (p<.05) from baseline are 
indicated with colored asterisks (*); the color of the asterisks corresponds with the condition 
in which a significant difference from baseline was observed. Asterisks and p-values refer to 
Bonferroni adjusted significance levels.
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